Abstract
The metabolic syndrome (MetS) is a cluster of metabolic abnormalities including abdominal obesity, glucose intolerance, hypertension and dyslipidaemia and is associated with an increased risk of vascular events. Since the initial description of the MetS, several expert groups produced different definitions. This variability led to confusion and absence of comparability between studies. Although there is agreement that the MetS is a major public health challenge worldwide and consistent evidence stresses the need for intervention, the definition of the syndrome remains a matter of debate. This review considers the different definitions of the MetS. These include those proposed by the World Health Organisation, the European Group for the Study of Insulin Resistance, the National Cholesterol Education Program Adult Treatment Panel III, the American College of Endocrinology and American Association of Clinical Endocrinologists and the latest International Diabetes Federation definition which includes ethnic-specific waist circumference cut-off points. These definitions share several features but also include important differences; all have limitations. Selected (after a Medline search) studies comparing the different definitions are also considered. There is a need for a standardised definition of the MetS. Furthermore, a definition tailored for children and adolescents is essential. Prospective long-term studies are needed to validate the prognostic power of these definitions. As new information becomes available the definition of the MetS might be further modified.
Keywords: Metabolic syndrome, insulin resistance syndrome, nsulin resistance, definition, vascular risk
Current Vascular Pharmacology
Title: Definitions of Metabolic Syndrome: Where are We Now?
Volume: 4 Issue: 3
Author(s): Stella S. Daskalopoulou, Vassilis G. Athyros, Genovefa D. Kolovou, Katherine K. Anagnostopoulou and Dimitri P. Mikhailidis
Affiliation:
Keywords: Metabolic syndrome, insulin resistance syndrome, nsulin resistance, definition, vascular risk
Abstract: The metabolic syndrome (MetS) is a cluster of metabolic abnormalities including abdominal obesity, glucose intolerance, hypertension and dyslipidaemia and is associated with an increased risk of vascular events. Since the initial description of the MetS, several expert groups produced different definitions. This variability led to confusion and absence of comparability between studies. Although there is agreement that the MetS is a major public health challenge worldwide and consistent evidence stresses the need for intervention, the definition of the syndrome remains a matter of debate. This review considers the different definitions of the MetS. These include those proposed by the World Health Organisation, the European Group for the Study of Insulin Resistance, the National Cholesterol Education Program Adult Treatment Panel III, the American College of Endocrinology and American Association of Clinical Endocrinologists and the latest International Diabetes Federation definition which includes ethnic-specific waist circumference cut-off points. These definitions share several features but also include important differences; all have limitations. Selected (after a Medline search) studies comparing the different definitions are also considered. There is a need for a standardised definition of the MetS. Furthermore, a definition tailored for children and adolescents is essential. Prospective long-term studies are needed to validate the prognostic power of these definitions. As new information becomes available the definition of the MetS might be further modified.
Export Options
About this article
Cite this article as:
Daskalopoulou S. Stella, Athyros G. Vassilis, Kolovou D. Genovefa, Anagnostopoulou K. Katherine and Mikhailidis P. Dimitri, Definitions of Metabolic Syndrome: Where are We Now?, Current Vascular Pharmacology 2006; 4 (3) . https://dx.doi.org/10.2174/157016106777698450
DOI https://dx.doi.org/10.2174/157016106777698450 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D in Acute Kidney Injury
Inflammation & Allergy - Drug Targets (Discontinued) The Antiplatelet and Antithrombotic Actions of Statins
Current Pharmaceutical Design Development and Characterization Pulsatile Microspheres of Nifedipine for Hypertension
Recent Patents on Drug Delivery & Formulation Modeling the Interactions Between α1-Adrenergic Receptors and Their Antagonists
Current Computer-Aided Drug Design Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Statins in Peripheral Arterial Disease
Current Pharmaceutical Design Hypertension and Diabetes: Emphasis on the Renin-Angiotensin System in Atherosclerosis
Current Hypertension Reviews Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Contraception in Women with Medical Conditions
Current Women`s Health Reviews CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Nitrite-stimulated Gastric Formation of S-nitrosothiols As An Antihypertensive Therapeutic Strategy
Current Drug Targets Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews Metal Oxide Nanoparticles: Potential Uses in Biomedical Applications
Current Proteomics Anti-hyperglycemic Properties of a Purified Proteinaceous Protease Inhibitor from Macrotyloma Uniflorum Seeds
Current Topics in Medicinal Chemistry Bioactive Small Molecules: Promising Novel Therapies in Cardiovascular Diseases – PART I
Current Topics in Medicinal Chemistry Review of Medicinal Plants Common to Traditional Chinese and Indian Medicines with Relevance to Non-Communicable Diseases
Current Traditional Medicine Endocannabinoid Metabolic Pathways and Enzymes
Current Drug Targets - CNS & Neurological Disorders